marijuana stock news

Oxis Biotech Inc. Announces Appointment of Dr. Lisa A. Haile to Scientific Advisory Board

TAMPA, Fla., Feb. 10, 2015 /PRNewswire/ — Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on cannabinoid therapy development and commercialization, announced today, Dr. Lisa A. Haile has joined the Scientific Advisory Board for its wholly owned subsidiary, Oxis Biotech, Inc.

Dr. Lisa A. Haile, Ph.D. currently serves as Co-Chair, Global Life Sciences Sector at DLA Piper. Dr. Haile has special technical expertise in molecular biology and immunology . She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management and value creation. Dr. Haile is a member of DLA Piper’s Executive Committee.

Dr. Haile’s experience includes US and international patent preparation and prosecution as well as IP reviews for investors relating to technologies including novel genetically altered organisms, antisense, RNA and siRNA molecules, peptides, proteins, DNA, antibodies, vaccines, diagnostics and therapeutics.

Oxis Chairman and CEO Tony Cataldo stated, “Intellectual Property is often generated as a result of the development of drug therapy during the evolution and preparation of moving a drug towards FDA approval. Dr. Haile is one of the top biotech attorneys in the world who also happens to be a molecular biologist giving her a more complete understanding of the issues that drive value to the process. We are pleased to add her to our Science Advisory Board.” (Joining Dr. Xaing-Quan Xie, and Dr. James Mule., see Oxis press releases).

“I am looking forward to joining the Oxis SAB and working with them as they move forward with research and development in important therapeutic areas, including new cancer therapies,” said Dr. Haile.

ABOUT OXIS BIOTECH, INC. – OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world’s leading cannabinoid researchers and institutions to advance it’s technologies.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


To view the original version on PR Newswire, visit:

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like



 Lexaria Bioscience Corp. (LXRP) Applies for NIH Grant for COVID-19 Therapy Studies

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives…

$TRTC Retains KCSA Strategic Communications as Investor Relations Counsel

Terra Tech Retains KCSA Strategic Communications as Investor Relations Counsel   Terra Tech…